OR WAIT 15 SECS
WuXi Vaccines, WuXi Biologics’ joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with a global vaccine leader for $3 billion.
WuXi Biologics announced on Feb. 18, 2020 that WuXi Vaccines, its joint venture with Shanghai Hile Bio-technology, has signed a 20-year vaccine manufacturing contract with an undisclosed global vaccine leader for $3 billion.
Under the terms of the contract, WuXi Vaccines will construct an integrated vaccine manufacturing facility for drug substance and drug product manufacturing that will include manufacturing science and technology labs as well as quality control labs, according to a company press release. The facility is set to be operational in 2022 and will focus on manufacturing vaccine products for WuXi Vaccines’ partner.
“This is a historic moment for WuXi Biologics and WuXi Vaccines as well as for the global vaccine industry. This partnership with a global vaccine leader to exclusively manufacture a vaccine for the global market, [the] first of its kind in the industry, is a further testimony to the technical strengths and premier quality demonstrated by WuXi Vaccines,” said Dr. Chris Chen, CEO of WuXi Biologics and chairman of WuXi Vaccines, in the press release. “WuXi Biologics together with WuXi Vaccines will continue to provide our global partners with a robust and premier-quality supply chain network to produce high quality biologic and vaccine products to benefit patients worldwide and to protect human beings globally, initially with therapeutic proteins and now with vaccines.”
Source: WuXi Biologics